Stock data
Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of US$172.35M and net income of -US$285.42M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$172.35M | — | -US$273.08M | -US$285.42M | — |
| 2024 | US$23.68M | — | -US$339.67M | -US$318.76M | — |
| 2023 | US$0.00M | — | -US$229.95M | -US$209.36M | — |
| 2022 | US$0.00M | — | -US$151.76M | -US$149.34M | — |
| 2021 | US$139.71M | — | US$26.22M | US$24.93M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$72.79M | -US$49.36M | — |
| 2026-03-31 | US$64.86M | -US$42.67M | — |
| 2025-12-31 | US$68.48M | -US$68.01M | — |
| 2025-09-30 | US$45.87M | -US$60.72M | — |
| 2025-06-30 | US$37.96M | -US$71.85M | — |
| 2025-03-31 | US$20.04M | -US$84.85M | — |
| 2024-12-31 | US$7.68M | -US$94.17M | — |
| 2024-09-30 | US$12.50M | -US$84.13M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.